27th Annual Pharmacological Conference for Advanced Practice Providers: Enduring Modules

Course ID: 22CE00002e
September 9th, 2022
Enduring Material

Paid ANCC Pharmacotherapeutic AAPA

Registration Starts on September 9th, 2022


  • 27th Annual Pharmacological Conference for Advanced Practice Providers
    Pharmacological Management of Clients across the Lifespan
    Enduring Modules
    Release date: September 9th, 2022
    Expiration date: September 8th, 2023
    Fee: $60 per module

    Course ID Module Action
    22CE00074 COVID & Antibiotics Enduring Module
    3.0 ANCC, 3.0 Pharmacotherapeutic, 3.0 AAPA
    22CE00075 Mental Health Enduring Module
    3.0 ANCC, 3.0 Pharmacotherapeutic, 3.0 AAPA
    22CE00076 Pain Management & PDMP Enduring Module
    3.0 ANCC, 3.0 Pharmacotherapeutic, 3.0 AAPA
    22CE00077 Hot Off the Press Enduring Module
    3.0 ANCC, 3.0 Pharmacotherapeutic, 3.0 AAPA

    Target Audience:

    Nurse practitioners, advanced practice nurses, physician assistants,
    primary care providers, and other interested healthcare professionals.



    The purpose of this enduring material is to enable the learner to use state-of-the-art clinical knowledge about pharmacology to manage selected, complex, acute, and chronic patient populations across the life span.

     Global Outcomes:

    • Discuss medical management approaches for the treatment of co-infections and secondary infections in patients with COVID-19 including evidence-based guidelines for antimicrobials and vaccinations using a case-based approach
    • Articulate best practice options when initiating mental health pharmaceuticals within primary care settings while considering patient health status and existing conditions pending psychiatric referral
    • Describe updates related to pharmacotherapeutics commonly prescribed in primary care for opioid and non-opioid management considering the PDMP and other existing conditions
    • Identify new approaches in primary care for comprehensive medication management when addressing multiple comorbidities such as afib, heart failure, cancers, and other ailments

    Method of Participation
    The estimated time to complete the activity is 180 minutes.

    • Read this front matter information
    • Register for activity
    • Click on Course Materials tab
    • Enter User ID and Password (issued after registering) and click "Login"
    • Participate in the entire learning activity
    • Complete the online evaluation for activity
    • Complete the post-test with a score of 7 out of 9 or better
    • Upon successful completion of the post-test and evaluation your certificate of completion will be available to print or save.

    Disclosure Information
    As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

    All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

    This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

    All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.


    The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:  

    Kevin Borcher, PharmD
    Consultant: Breezemed

    Sherri Thomas, DO
    Speakers Bureau: Nova Nordisk & Rhythm Pharmaceuticals

    The below faculty have nothing to disclose:

    • Lauren Bodhaine-Haywood, PharmD, BCOP, BCPS
    • Heather Chambers, DNP, APRN-NP, FNP-C*
    • Daniel Cramer, MSN, RN, APRN-C, FNP
    • Kristin Daniel, PharmD, BCPS, DPLA
    • Ally Dering-Anderson, BA, PharmD, RP, FAPhA
    • Teri Diederich, APRN-NP, CHFN, FHFSA*
    • Marley Doyle, MD
    • Alisandrea Elson, MD
    • Margaret Emerson, DNP, APRN, PMHNP-BC*
    • Meghan Luebbert, DNP, APRN-NP, PMHNP-BC
    • Katie McGill, FNP-C, APRN, BSN
    • Melissa O’Dell, MD
    • Dana Raml, MD

    *Faculty and planning committee member


    The below planning committee members have nothing to disclose:

    • Rita Antonson, MSN, APRN, GNP-BC
    • Mary Carlson, FNP, MSN, BSN
    • Lois Dauel, APRN, BSN
    • Wende Heckert, DNP, APRN-NP
    • LeAnn Holmes, DNP, APRN,FAANP
    • Kassidy Horst, APRN, WHNP-BC, FNP-C
    • Heidi Keeler, PhD, RN
    • Kathy Murphy-Buschkoetter, DNP, APRN, FNP-BC
    • Elizabeth Murphy-Blake, MSEd, MS, APRN-NP
    • Renee Paulin, MSN, RN, CWOCN
    • Courtney Smith
    • Kathleen Yao, DNP, APRN-NP, WHNP-BC
    • Risa Zimmerman, MBA, MPAS, PA-C

    Lauren Bodhaine-Haywood, PharmD, BCOP, BCPS

    Prednisone/methylprednisolone: Treatment of immune-related toxicities per NCCN